Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
ORION CORPORATION PRESS RELEASE 18 DECEMBER 2024 at 17.00 EET Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics ...
Medindia1d
Abilita Therapeutics and Orion Announce Research Collaboration to Develop Next-Generation Antibody Therapeutics in the Areas of Oncology and Pain
Abilita Therapeutics, Inc. ("Abilita") today announced a global licensing and multi-target research collaboration with Finnish Orion Corporation ("Orion") focused on the discovery, development and ...
Taiwan News2d
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Under the terms of the agreement, Orion gains access to Abilita’s proprietary Enabled Membrane Protein (EMP™) technology for the discovery of novel antibody therapeutics to challenging GPCR (G protein ...
Business Insider2d
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Under the terms of the agreement, Orion gains access to Abilita’s proprietary Enabled Membrane Protein (EMP™) technology for the discovery of novel antibody therapeutics to challenging GPCR (G ...
Finanznachrichten2d
Orion Oyj: Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics Orion Corporation ("Orion") and Abilita Therapeutics ...